Xeris Biopharma Holdings (XERS) Current Leases (2022 - 2026)
Xeris Biopharma Holdings' (XERS) quarterly Current Leases came in at $6.3 million in Q1 2026, up 2.52% YoY from $6.1 million in Q1 2025, and up 0.63% on a QoQ basis from $6.2 million in Q4 2025.
Xeris Biopharma Holdings (XERS) Current Leases (2022 - 2026) Analysis & Trends
Xeris Biopharma Holdings (XERS) has 5 years of Current Leases data on file, last reported at $6.3 million in Q1 2026.
- Quarterly Current Leases rose 2.52% year-over-year to $6.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $6.3 million (up 2.52% YoY) and the FY2025 annual result came in at $6.2 million, up 2.5% from the prior year.
- Current Leases rose to $6.3 million in Q1 2026, from $6.2 million in the prior quarter.
- In the past five years, Current Leases ranged from a high of $6.3 million in Q1 2026 to a low of $1.4 million in Q1 2023.
- A 5-year average of $4.6 million and a median of $5.7 million in 2024 frame the typical range for Current Leases.
- Annual changes were most pronounced in 2024 — Current Leases jumped 219.34% — and 2025, when it climbed 2.5%.
- Tracing XERS's Current Leases over 5 years: stood at $1.6 million in 2022, then jumped by 121.2% to $3.5 million in 2023, then jumped by 73.96% to $6.1 million in 2024, then increased by 2.5% to $6.2 million in 2025, then advanced by 0.63% to $6.3 million in 2026.
- The last three Current Leases figures came in at $6.3 million (Q1 2026), $6.2 million (Q4 2025), and $6.2 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Leases (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | - |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | - |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | - |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | - |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | - |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | - |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | - |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | Xeris Biopharma Holdings | 1.48 Bn | 1.36 Bn | 79.59 Mn | 6.31 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 6.31 Mn |
| Mar 31, 2026 | 6.27 Mn |
| Dec 31, 2025 | 6.23 Mn |
| Sep 30, 2025 | 6.19 Mn |
| Jun 30, 2025 | 6.16 Mn |
| Mar 31, 2025 | 6.12 Mn |
| Dec 31, 2024 | 6.08 Mn |
| Sep 30, 2024 | 6.04 Mn |
| Jun 30, 2024 | 5.31 Mn |
| Mar 31, 2024 | 4.62 Mn |
| Dec 31, 2023 | 3.50 Mn |
| Sep 30, 2023 | 2.37 Mn |
| Jun 30, 2023 | 1.94 Mn |
| Mar 31, 2023 | 1.45 Mn |
| Dec 31, 2022 | 1.58 Mn |